他汀类药物在冠心病合并糖尿病患者治疗中的应用(1)
[摘要] 目的 探讨他汀类药物在冠心病合并糖尿病患者治疗中的应用与效果。方法 选取该科2016年11月—2017年11月收治的冠心病合并糖尿病患者128例，随机分为两组各64例，对照组给予常规治疗，观察组在对照组的基础上给予他汀类药物。结果 治疗后观察组FPG(5.21±0.78)mmol/L、TC(5.35±0.16)mmol/L、TG(1.18±0.44)mmol/L、LDL-C(2.79±0.19)mmol/L较对照组显著降低，HDL-C(1.88±0.33)mmol/L较对照组显著升高(P<0.05)；观察组不良事件发生率为7.8%，明显少于对照组21.9%(P<0.05)。结论 对冠心病合并糖尿病患者给予他汀类药物，可有效降低血脂水平，减少心血管不良事件的发生，值得应用。
[关键词] 他汀类；冠心病；糖尿病
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2018)02(b)-0078-02
Application of Statins in the Treatment of Coronary Heart Disease Complicated with Diabetes
CUI Wen-zhang
Department of Cardiovascular Medicine， Jilin People's Hospital， Changchun， Jilin Province， 130000 China
[Abstract] Objective This paper tries to investigate the application and effect of statins in the treatment of patients with coronary heart disease and diabetes. Methods 128 patients with coronary heart disease and diabetes mellitus admitted to this hospital from November 2016 to November 2017 were selected and were randomly divided into two groups of 64 patients in each. The control group was given conventional treatment. The observation group was given statins based on the control group. Results After treatment， FPG (5.21±0.78)mmol/L， TC (5.35±0.16)mmol/L， TG (1.18±0.44)mmol/L， and LDL-C (2.79±0.19)mmol/L were significantly lower in the observation group than in the control group. HDL-C(1.88±0.33)mmol/L was significantly higher than that in the control group(P<0.05). The incidence of adverse events in the observation group was 7.8%， which was significantly less than 21.9% in the control group(P<0.05). Conclusion Giving statins to patients with coronary heart disease and diabetes can effectively reduce blood lipid levels and reduce the incidence of cardiovascular adverse events. It is worth applying.
[Key words] Statins； Coronary Heart Disease； Diabetes
近年來，随着我国人群生活和饮食习惯的改变，糖尿病和冠心病的发生率不断呈上升趋势。糖尿病是冠心病的危险因素之一，据报道[1]，糖尿病患者发生冠心病的机率是非糖尿病患者的4倍，死亡率是5～6倍；高血脂、高胆固醇是冠心病发生的关键影响因素，其可增加糖尿病罹患心血管风险，还能加重糖尿病病情，使血糖进一步升高。两种疾病合并发生时往往相互影响，相互恶化，使病情不断加重，严重影响死亡率和预后。临床研究表明[2]，他汀类药物是冠心病、糖尿病一级和二级预防、治疗的关键药物[3]，其在稳定、逆转动脉硬化斑块，减轻血管狭窄损伤，增加心肌灌注等方面具有显著效果，从而预防和减少心血管事件发生。该文对该科2016年11月—2017年11月收治的64例冠心病合并糖尿病患者采用他汀类药物治疗，探讨他汀类药物在冠心病合并糖尿病患者治疗中的效果，报道如下。
1 资料与方法
1.1 一般资料
选取该科收治的冠心病合并糖尿病患者128例为观察对象，随机将患者分为两组各64例，观察组男44例，女20例，年龄36～82岁，平均(55.6±1.2)岁，糖尿病病程3～15年，平均(8.9±1.0)年，冠心病病程1～6年，平均(3.6±1.1)年；对照组男41例，女23例，年龄35～80岁，平均(54.7±1.5)岁，糖尿病病程3～14年，平均(8.2±1.3)年，冠心病病程1～5.5年，平均(3.2±1.3)年。该组患者均经冠脉造影检查确诊至少一条冠状动脉的直径狭窄超过50%，且未服用过他汀类药物控制血脂；排除肝肾功能异常、心衰、肿瘤、风湿性心脏病、心肌病、甲状腺功能异常等患者。患者对治疗均知情同意并经伦理委员会批准。两组患者一般资料比较差异无统计学意义(P>0.05)。, http://www.100md.com(崔文章)
[关键词] 他汀类；冠心病；糖尿病
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2018)02(b)-0078-02
Application of Statins in the Treatment of Coronary Heart Disease Complicated with Diabetes
CUI Wen-zhang
Department of Cardiovascular Medicine， Jilin People's Hospital， Changchun， Jilin Province， 130000 China
[Abstract] Objective This paper tries to investigate the application and effect of statins in the treatment of patients with coronary heart disease and diabetes. Methods 128 patients with coronary heart disease and diabetes mellitus admitted to this hospital from November 2016 to November 2017 were selected and were randomly divided into two groups of 64 patients in each. The control group was given conventional treatment. The observation group was given statins based on the control group. Results After treatment， FPG (5.21±0.78)mmol/L， TC (5.35±0.16)mmol/L， TG (1.18±0.44)mmol/L， and LDL-C (2.79±0.19)mmol/L were significantly lower in the observation group than in the control group. HDL-C(1.88±0.33)mmol/L was significantly higher than that in the control group(P<0.05). The incidence of adverse events in the observation group was 7.8%， which was significantly less than 21.9% in the control group(P<0.05). Conclusion Giving statins to patients with coronary heart disease and diabetes can effectively reduce blood lipid levels and reduce the incidence of cardiovascular adverse events. It is worth applying.
[Key words] Statins； Coronary Heart Disease； Diabetes
近年來，随着我国人群生活和饮食习惯的改变，糖尿病和冠心病的发生率不断呈上升趋势。糖尿病是冠心病的危险因素之一，据报道[1]，糖尿病患者发生冠心病的机率是非糖尿病患者的4倍，死亡率是5～6倍；高血脂、高胆固醇是冠心病发生的关键影响因素，其可增加糖尿病罹患心血管风险，还能加重糖尿病病情，使血糖进一步升高。两种疾病合并发生时往往相互影响，相互恶化，使病情不断加重，严重影响死亡率和预后。临床研究表明[2]，他汀类药物是冠心病、糖尿病一级和二级预防、治疗的关键药物[3]，其在稳定、逆转动脉硬化斑块，减轻血管狭窄损伤，增加心肌灌注等方面具有显著效果，从而预防和减少心血管事件发生。该文对该科2016年11月—2017年11月收治的64例冠心病合并糖尿病患者采用他汀类药物治疗，探讨他汀类药物在冠心病合并糖尿病患者治疗中的效果，报道如下。
1 资料与方法
1.1 一般资料
选取该科收治的冠心病合并糖尿病患者128例为观察对象，随机将患者分为两组各64例，观察组男44例，女20例，年龄36～82岁，平均(55.6±1.2)岁，糖尿病病程3～15年，平均(8.9±1.0)年，冠心病病程1～6年，平均(3.6±1.1)年；对照组男41例，女23例，年龄35～80岁，平均(54.7±1.5)岁，糖尿病病程3～14年，平均(8.2±1.3)年，冠心病病程1～5.5年，平均(3.2±1.3)年。该组患者均经冠脉造影检查确诊至少一条冠状动脉的直径狭窄超过50%，且未服用过他汀类药物控制血脂；排除肝肾功能异常、心衰、肿瘤、风湿性心脏病、心肌病、甲状腺功能异常等患者。患者对治疗均知情同意并经伦理委员会批准。两组患者一般资料比较差异无统计学意义(P>0.05)。, http://www.100md.com(崔文章)